Mutations in NFKBIA (IκBα) and BIRC3 (cIAP2) are believed to exert a more potent effect on NF-κB signalling and inflammation compared with other negative regulators of the pathway, such as TRAF3 and CYLD. This dysregulation may promote tumour survival and progression. Here, CYLD is linked to neoplasm.